Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib

@article{Billemont2008BloodGL,
  title={Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib},
  author={Bertrand Billemont and Jacques M{\'e}dioni and Laurent Taillade and Dominique Helley and Julien M{\'e}ric and Olivier Rixe and St{\'e}phane Oudard},
  journal={British Journal of Cancer},
  year={2008},
  volume={99},
  pages={1380 - 1382}
}
  • Bertrand Billemont, Jacques Médioni, +4 authors Stéphane Oudard
  • Published in British Journal of Cancer 2008
  • Medicine
  • Sunitinib, a multitargeted tyrosine-kinase inhibitor, extends survival of patients with metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal tumours. Between October 2005 and March 2007, we retrospectively reviewed blood glucose level variations associated with sunitinib therapy in patients treated for mRCC. Nineteen of the patients had type II diabetes. All 19 patients had a decrease in blood glucose level (mean 1.77 mmol l−1) after 4 weeks of treatment. This was followed by re… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 46 CITATIONS

    Impact of sunitinib treatment on blood glucose levels in patients with metastatic renal cell carcinoma.

    VIEW 5 EXCERPTS
    CITES BACKGROUND & RESULTS
    HIGHLY INFLUENCED

    Sunitinib in Special Situations in their Daily Practice

    VIEW 5 EXCERPTS
    CITES BACKGROUND & RESULTS
    HIGHLY INFLUENCED

    Life-threatening hypoglycemia induced by a tyrosine kinase inhibitor in a patient with neuroendocrine tumor: a case report.

    VIEW 4 EXCERPTS
    CITES BACKGROUND
    HIGHLY INFLUENCED

    Cardiotoxicity with vascular endothelial growth factor inhibitor therapy

    VIEW 1 EXCERPT
    CITES BACKGROUND

    Transformation of a non-secretory neuroendocrine tumor to insulinoma after treatment with Sunitinib: A case report and review of the literature

    VIEW 1 EXCERPT
    CITES BACKGROUND

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 12 REFERENCES

    Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

    VIEW 4 EXCERPTS

    Mechanisms of Disease: using genetically altered mice to study concepts of type 2 diabetes

    VIEW 1 EXCERPT

    Remission of diabetes while on sunitinib treatment for renal cell carcinoma.

    VIEW 1 EXCERPT

    Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning.

    VIEW 1 EXCERPT

    Non-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinib.

    VIEW 1 EXCERPT